Advances in Clinical and Experimental Medicine

Adv Clin Exp Med
Impact Factor (IF) – 1.227
Index Copernicus (ICV 2018) – 157.72
MNiSW – 40
Average rejection rate – 84.38%
ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download PDF

Advances in Clinical and Experimental Medicine

2014, vol. 23, nr 1, January-February, p. 127–133

Publication type: review article

Language: English

Immunoglobulin Heavy Chain/Light Chain Pairs (Hlc, Hevylitetm) Assays for Diagnosing and Monitoring Monoclonal Gammopathies

Maria Kraj1,

1 Institute of Hematology and Transfusion Medicine, Warsaw, Poland

Abstract

Immunofixation (IFE) is a standard method for detecting monoclonal immunoglobulins and characterizing its isotype. Recently clonality can also be determined by using immunoglobulin (Ig) heavy chain/light chain immunoassays – HLC, HevyliteTM. HLC separately measures in pairs light chain types of each intact Ig class generating ratios of monoclonal Ig/uninvolved polyclonal Ig concentrations. Studies have shown that HLC and IFE are complementary methods. HLC assays quantify monoclonal proteins and identify monoclonality. It is possible to predict prognosis in multiple myeloma and to monitor response to treatment using HLC ratio. HLC ratio may serve as a parameter for myeloma induced immunoparesis and serve as a new marker for validating remission depth and relapse probabilities.

Key words

hevylite, free light chains, monoclonal gammopathy, multiple myeloma, remission.

References (37)

  1. Katzmann JA, Kyle RA, Benson J, Larson DR, Snyder MR, Lust JA: Screening panels for detection of monoclonal gammopathies. Clin Chem 2009, 55, 1517–1522.
  2. Narayan S, Lujan MG, Baskin LB, Devaraj S, Rutherford C, Jialal I, et al.: Measurement of β1 and β2-globulins improves detection of M-spikes on high-resolution electrophoresis. Clin Chem 2003, 49, 676–678.
  3. Keren DF.: Heavy/light-chain analysis of monoclonal gammopathies. Clin Chem 2009, 55, 1606–1608.
  4. Keren DF, Humphrey RL: Clinical indications and applications of serum and urine protein electrophoresis. In: Manual of clinical immunology. Eds. Folds EC, Hamilton JD, Dietrich R, Washington (DC): ASM Press, 2006, 7th ed., p 75–87.
  5. Bradwell AR: Serum free light chain analysis (plus Hevylite) 6th Edition. The Binding Site Group Ltd, Birmingham, UK 2010 (Wikilite.com).
  6. Bradwell AR, Harding SJ, Fourrier NJ, Gregg LF, Wallis GLF, Drayson MT, et al.: Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin κ/λ ratios. Clin Chem 2009, 55, 1646–1655.
  7. Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, et al.: Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001, 47, 673–680.
  8. Koulieris E, Kyrtsonis MCh, Maltezas D, Tzenou T, Mirbahai L, Kafassi N, et al.: Quantification of serum IgMκ and IgMλ in patients with Waldenstrőm’s Macroglobulinemia (WM) at diagnosis and during disease course; clinical correlations. Blood 2010, 116, 1238 (abstract 3004).
  9. Suvannasankha A, Farag S, Harding S, Durie BGM, Abonour R: Assessment of the performance of serum heavy chains immunoassay to monitor response to treatment and its correlation with other tumor measurements in serial samples from patients with newly diagnosed MM. Blood 2010, 116, 1231 (abstract 2986)
  10. Planche V, Arnaud L, Viala K: Hevylite as a biomarker for monitoring patients with IgM monoclonal gammopathy and anti-MAG neuropathy. Haematologica 2012, 97 e-Suppl. 1, 14–17, 683.
  11. Kraj M, Kruk B, Pogłód R, Warzocha K: Evaluation of IgG, IgA and IgM monoclonal and biclonal gammopathies by nephelometric measurement of individual immunoglobulin κ/λ ratios – Hevylite assay verus immunofixation. Acta Haematol Pol 2011, 42, 257–271.
  12. Wechalekar A, Harding S, Lachmann H, Gillmore J, Wassef NJ, Thomas M, et al.: Serum immunoglobulin heavy/light chain ratios (Hevylite) in patients with systemic AL amyloidosis. Amyloid 2010, 17, P 186a.
  13. Kraj M, Kruk B, Pogłód R, Szczepiński A: Correlation of serum immunoglobulin free light chain quantification with serum and urine immunofixation in monoclonal gammopathies. Acta Haematol Pol 2011, 42, 273–283.
  14. Kraj M, Kruk B, Pogłód R: Clinical value of serum immunoglobulin free light chain quantification in multiple myeloma. Nowotwory J Oncol 2011, 61, 4, 52e–58e (355–362).
  15. Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, Kyle RA.: Serum reference intervals and diagnostic ranges for free κ and free λ immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002, 48, 1437–1444.
  16. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al.: International uniform response criteria for multiple myeloma. Leukemia 2006, 20, 1467 – 1473.
  17. Kumar S, Dispenzieri A, Larson D, Colby CL, Kyle R, Gertz M, Rajkumar SV: Normalization of the serum free light chain ratio is associated with superior overall survival among myeloma patients achieving immunofixation negative state: results support incorporation of serum free light chain ratio in stringent CR definition. Blood 2008, 112, 1692.
  18. Kraj M, Kruk B, Szczepiński A, Warzocha K: Comparison of immunoglobulin free light chain (FLC), heavy chain/light chain (HLC) assays and immunofixation (IFE) in assessment of remission in multiple myeloma. Acta Haematol Pol 2012, 43 (2a), 122–131.
  19. Avet – Loiseau H, Mirbahai I, Mathiot C, Attal M, Moreau P, Harousseau JL, Bradwell A, Harding S: Nephelometric assays Ig’κ and Ig’λ used for diagnosing and monitoring multiple myeloma. Haematologica 2011, 96, Suppl 1, S144 (abstract 393).
  20. Decaux O, Besnard S, Beaumont MP, Collet N, Sebillot M, Grosbois B, Guenet L: Serial sample analysis of 15 multiple myeloma patients using heavy/light chain specific immunoglobulin ratios (HevyliteTM). Contribution to the evaluation of response to treatment. Haematologica 2011, 96, Suppl 1, s43 (abstract 039).
  21. Olivero B, Robillard N, Wuilleme S, Avet-Loiseau H, Attal M, Roussel M, Dejoie T: Heavy/light chain assay, potential new tool in minimal residual disease assessment. A biological study from IFM 2008 trial. Haematologica 2011, 96, Suppl 1, s52 (abstract 079).
  22. Tovar N, Fernández de Larrea C, Elena M, Cibeira MT, Aróstegui JI, Rosiňol L: Prognostic impact of serum immunoglobulin heavy/light chains ratio in patients with multiple myeloma in complete remission after stem-cell transplantation. Haematologica 2012, 97, e-Suppl 1, June 14–17, 394.
  23. Seetharam A, Mirbahai I, Lovatt T, Macwhannell A, Jacob A, Handa S, Harding S, Basu S: Heavy/light chain ratios provide a rapid and sensitive alternative to IFE in identifying haematological malignancies. Haematologica 2011, 96, Suppl 1, s53 (abstract 080).
  24. Ludwig H, Faint J, Zojer N, Bradwell A, Milosavljevic D, Harding S: Immunoglobulin heavy/light chain ratios effectively monitor disease and provide prognostic information in multiple myeloma patients. Haematologica 2011, 96, Suppl 1, S142 (abstract 386).
  25. Koulieris E, Harding S, Bartzis V, Tzenou T, Mead G, Mirbahai I, Bradwell AR, Panagyiotidis P, Kyrtsonis MC: Contribution of novel M-component based biomarkers in detection of relapse in multiple myeloma. Haematologica 2011, 96, Suppl 1, s136 (abstract 365).
  26. Willenbacher E, Prokop W, Willenbacher W: Skewed hevylite ratios may sensitively predict early relapse: a first case report and outline for further studies. Haematologica 2011, 96, Suppl 1, S171 (abstract A-482).
  27. Hari P, Pasquini MC, Logan BR, Stadtmauer EA, Krishnan A, Howard A: Immunoglobulin free light chain (FLC) and heavy chain/light chain (HLC) assays – comparison with electrophoretic response in multiple myeloma. Blood 2011, 118, 1241 (abstract 2877).
  28. Koulieris E, Harding S, Tzenou T, Maltezas D, Bartzis V, Dimou M, Mead G, Mirbahai I, Bradwell AR, Panayiotidis P, Kyrtsonis MC: Impact of novel M-component based biomarkers (HevyliteTM) on to progression free survival (PFS) after treatment in multiple myeloma patients. Haematologica 2011, 96, Suppl 1, S150 (abstract 413).
  29. Avet-Loiseau H, Harousseau J-L, Moreau P, Mathiot C, Facon T, Attal M, Bradwell A: Heavy/light chain specific immunoglobulin ratios at presentation are prognostic for progression free survival in the IFM 2005-01 myeloma trial. Blood 2009, 114, 722 (abstract 1818).
  30. Avet-Loiseau H, Mirbahai L, Harousseau JL, Moreau P, Mathiot C, Facon T: Serum immunoglobulin heavy/ light chain ratios are independent risk factors for predicting progression free survival in multiple myeloma. Haematologica 2010, 95 (s2), 395 (abstract 0953).
  31. Ludwig H, Mirbahai L, Zojer N, Bradwell A, Harding S: The ratio of monoclonal to polyclonal immunoglobulins assessed with the Hevylite test predicts prognosis, is superior for monitoring the course of the disease and allows detection of monoclonal immunoglobulin in patients with normal and subnormal involved immunoglobulin isotype. Blood 2010, 116, 1646 (abstract 4038), Leukemia 2013, 27, 213–219.
  32. Ludwig H, Faint J, Zojer N, Bradwell AR, Young P, Milosavljevic D: Serum heavy/light chain and free light chain measurements provide prognostic information, allow creation of a prognostic model and identify clonal changes (clonal tiding) through the course of multiple myeloma Blood 2011, 118, 1244 (abstract 2883).
  33. Kraj M, Kruk B, Prochorec-Sobieszek M: Serum immunoglobulin heavy/light chain (HLC) and free light chain (FLC) concentrations at diagnosis in multiple myeloma and IgM malignant lymphoma patients with survival exceeding 10 years. Acta Haematol Pol 2012,43 (2b), 201–209.
  34. Koulieris E, Kyrtsonis MCh, Maltezas D, Tzenou T, Mirbahai L, Kafassi N: Quantification of serum IgMκ and IgMλ in patients with Waldenstrőm’s Macroglobulinemia (WM) at diagnosis and during disease course; clinical correlations. Blood 2010, 116, 1238 (abstract 3004).
  35. Leleu X, Koulieris E, Maltezas D, Itzykson R, Xie W, Manier S: Novel M-component based biomarkers in Waldenström’s Macroglobulinemia. Clinical Lymphoma Myeloma and Leukemia 2011, 11(1), 164–167.
  36. Katzmann J, Clark R, Dispenzieri A, Kyle R, Landgren O, Bradwell A, Rajkumar SV: Isotype – specific heavy/ /light chain (HLC) suppression as a predictor of myeloma development in monoclonal gammopathy of undetermined significance (MGUS). Blood 2009, 114, 711 (abstract 1788).
  37. Jardin F, Delfau – Larue M, Jais J, Leroy K, Borrel A, Molina T: Immunoglobulin heavy chain/light chain pairs measurement is associated with survival in diffuse large B-cell lymphoma : analysis of a large cohort included in the LNH03-B program of the GELA. Haematologica 2012, 97, e-Suppl. 1, June 14–17, 108.